FDA: Delirium Tied to Use of Tamiflu in Influenza

Article

The U.S. Food and Drug Administration, together with Roche Laboratories, Inc., the maker of Tamiflu (oseltamivir), have informed health care professionals of neuropsychiatric events associated with use of the antiviral drug in patients with influenza. The Tamiflu package insert has been updated to reflect these safety concerns.

Recent Videos
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Jillian Cotter, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Tina Tan, MD
Danielle Van Damme, DNP, CPNP-AC
Karen Y. Capusan, DNP, CPNP-PC
Measles outbreaks: 223 cases reported in Texas | Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN
Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
 Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP
Related Content
© 2025 MJH Life Sciences

All rights reserved.